OBJECTIVES: To investigate the effect of a medical food (Souvenaid) on body mass index (BMI) and functional abilities in patients with mild Alzheimer's disease (AD). DESIGN/SETTING/PARTICIPANTS/INTERVENTION /MEASUREMENTS: These analyses were performed on data from a 12-week, double-blind, randomized, controlled, multicenter, proof-of-concept study with a similarly designed and exploratory 12-week extension period. Patients with mild AD (Mini-Mental State Examination score of 20-26) were randomized to receive either the active product or an iso-caloric control product. While primary outcomes included measures of cognition, the 23-item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale was included as a secondary outcome. Both ADCS-ADL and BMI were assessed at baseline and Weeks 6, 12 and 24. Data were analyzed using a repeated-measures mixed model. RESULTS: Overall, data suggested an increased BMI in the active versus the control group at Week 24 (ITT: p = 0.07; PP: p = 0.03), but no treatment effect on ADCS-ADL was observed. However, baseline BMI was found to be a significant treatment effect modifier (ITT: p = 0.04; PP: p = 0.05), and an increase in ADCS-ADL was observed at Week 12 in patients with a 'low' baseline BMI (ITT: p = 0.02; PP: p = 0.04). CONCLUSIONS: These data indicate that baseline BMI significantly impacts the effect of Souvenaid on functional abilities. In addition, there was a suggestion that Souvenaid increased BMI.
RCT Entities:
OBJECTIVES: To investigate the effect of a medical food (Souvenaid) on body mass index (BMI) and functional abilities in patients with mild Alzheimer's disease (AD). DESIGN/SETTING/PARTICIPANTS/INTERVENTION /MEASUREMENTS: These analyses were performed on data from a 12-week, double-blind, randomized, controlled, multicenter, proof-of-concept study with a similarly designed and exploratory 12-week extension period. Patients with mild AD (Mini-Mental State Examination score of 20-26) were randomized to receive either the active product or an iso-caloric control product. While primary outcomes included measures of cognition, the 23-item Alzheimer's Disease Cooperative Study-Activities of Daily Living (ADCS-ADL) scale was included as a secondary outcome. Both ADCS-ADL and BMI were assessed at baseline and Weeks 6, 12 and 24. Data were analyzed using a repeated-measures mixed model. RESULTS: Overall, data suggested an increased BMI in the active versus the control group at Week 24 (ITT: p = 0.07; PP: p = 0.03), but no treatment effect on ADCS-ADL was observed. However, baseline BMI was found to be a significant treatment effect modifier (ITT: p = 0.04; PP: p = 0.05), and an increase in ADCS-ADL was observed at Week 12 in patients with a 'low' baseline BMI (ITT: p = 0.02; PP: p = 0.04). CONCLUSIONS: These data indicate that baseline BMI significantly impacts the effect of Souvenaid on functional abilities. In addition, there was a suggestion that Souvenaid increased BMI.
Authors: Richard J Wurtman; Ismail H Ulus; Mehmet Cansev; Carol J Watkins; Lei Wang; George Marzloff Journal: Brain Res Date: 2006-04-21 Impact factor: 3.252
Authors: R C Mohs; D Knopman; R C Petersen; S H Ferris; C Ernesto; M Grundman; M Sano; L Bieliauskas; D Geldmacher; C Clark; L J Thal Journal: Alzheimer Dis Assoc Disord Date: 1997 Impact factor: 2.703
Authors: Philip Scheltens; Patrick J G H Kamphuis; Frans R J Verhey; Marcel G M Olde Rikkert; Richard J Wurtman; David Wilkinson; Jos W R Twisk; Alexander Kurz Journal: Alzheimers Dement Date: 2010-01 Impact factor: 21.566
Authors: P Barberger-Gateau; C Raffaitin; L Letenneur; C Berr; C Tzourio; J F Dartigues; A Alpérovitch Journal: Neurology Date: 2007-11-13 Impact factor: 9.910
Authors: E Droogsma; D Z B van Asselt; C J M Schölzel-Dorenbos; J H M van Steijn; P E van Walderveen; C S van der Hooft Journal: J Nutr Health Aging Date: 2013-07 Impact factor: 4.075
Authors: C W Ritchie; J Bajwa; G Coleman; K Hope; R W Jones; M Lawton; M Marven; P Passmore Journal: J Nutr Health Aging Date: 2014-03 Impact factor: 4.075
Authors: Jeffrey L Cummings; Richard S Isaacson; Frederick A Schmitt; Drew M Velting Journal: Ann Clin Transl Neurol Date: 2015-01-23 Impact factor: 4.511